73 related articles for article (PubMed ID: 15749453)
1. Hepatotoxicity and metabolism of trabectedin: a literature review.
Beumer JH; Schellens JH; Beijnen JH
Pharmacol Res; 2005 May; 51(5):391-8. PubMed ID: 15749453
[TBL] [Abstract][Full Text] [Related]
2. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
[TBL] [Abstract][Full Text] [Related]
3. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment.
Fetterly GJ; Owen JS; Stuyckens K; Passarell JA; Zannikos P; Soto-Matos A; Izquierdo MA; Perez-Ruixo JJ
Cancer Chemother Pharmacol; 2008 Jun; 62(1):135-47. PubMed ID: 17922277
[TBL] [Abstract][Full Text] [Related]
4. Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity.
Lee JK; Leslie EM; Zamek-Gliszczynski MJ; Brouwer KL
Toxicol Appl Pharmacol; 2008 Apr; 228(1):17-23. PubMed ID: 18191164
[TBL] [Abstract][Full Text] [Related]
5. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.
David-Cordonnier MH; Gajate C; Olmea O; Laine W; de la Iglesia-Vicente J; Perez C; Cuevas C; Otero G; Manzanares I; Bailly C; Mollinedo F
Chem Biol; 2005 Nov; 12(11):1201-10. PubMed ID: 16298299
[TBL] [Abstract][Full Text] [Related]
6. Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma.
Donald S; Verschoyle RD; Greaves P; Colombo T; Zucchetti M; Falcioni C; Zaffaroni M; D'Incalci M; Manson MM; Jimeno J; Steward WP; Gescher AJ
Int J Cancer; 2004 Oct; 111(6):961-7. PubMed ID: 15300810
[TBL] [Abstract][Full Text] [Related]
7. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
Reid JM; Kuffel MJ; Ruben SL; Morales JJ; Rinehart KL; Squillace DP; Ames MM
Clin Cancer Res; 2002 Sep; 8(9):2952-62. PubMed ID: 12231541
[TBL] [Abstract][Full Text] [Related]
8. In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.
Albella B; Faircloth G; López-Lázaro L; Guzmán C; Jimeno J; Bueren JA
Eur J Cancer; 2002 Jul; 38(10):1395-404. PubMed ID: 12091072
[TBL] [Abstract][Full Text] [Related]
9. Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro.
Donald S; Verschoyle RD; Greaves P; Orr S; Jimeno J; Gescher AJ
Cancer Chemother Pharmacol; 2004 Apr; 53(4):305-12. PubMed ID: 14669039
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer.
Beumer JH; Rademaker-Lakhai JM; Rosing H; Hillebrand MJ; Bosch TM; Lopez-Lazaro L; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2007 May; 59(6):825-37. PubMed ID: 16988825
[TBL] [Abstract][Full Text] [Related]
11. Editorial comment on "In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results" by Albella and colleagues.
D'Incalci M
Eur J Cancer; 2002 Jul; 38(10):1297. PubMed ID: 12091058
[No Abstract] [Full Text] [Related]
12. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
Beumer JH; Lopez-Lazaro L; Schellens JH; Beijnen JH; van Tellingen O
Curr Clin Pharmacol; 2009 Jan; 4(1):38-42. PubMed ID: 19149499
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
[TBL] [Abstract][Full Text] [Related]
15. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.
Grosso F; Dileo P; Sanfilippo R; Stacchiotti S; Bertulli R; Piovesan C; Jimeno J; D'Incalci M; Gescher A; Casali PG
Eur J Cancer; 2006 Jul; 42(10):1484-90. PubMed ID: 16737808
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
Puchalski TA; Ryan DP; Garcia-Carbonero R; Demetri GD; Butkiewicz L; Harmon D; Seiden MV; Maki RG; Lopez-Lazaro L; Jimeno J; Guzman C; Supko JG
Cancer Chemother Pharmacol; 2002 Oct; 50(4):309-19. PubMed ID: 12357306
[TBL] [Abstract][Full Text] [Related]
17. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.
Donald S; Verschoyle RD; Greaves P; Gant TW; Colombo T; Zaffaroni M; Frapolli R; Zucchetti M; D'Incalci M; Meco D; Riccardi R; Lopez-Lazaro L; Jimeno J; Gescher AJ
Cancer Res; 2003 Sep; 63(18):5902-8. PubMed ID: 14522916
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Sessa C; De Braud F; Perotti A; Bauer J; Curigliano G; Noberasco C; Zanaboni F; Gianni L; Marsoni S; Jimeno J; D'Incalci M; Dall'ó E; Colombo N
J Clin Oncol; 2005 Mar; 23(9):1867-74. PubMed ID: 15774779
[TBL] [Abstract][Full Text] [Related]
19. ABCC2, ABCC3, and ABCB1, but not CYP3A, Protect against Trabectedin-Mediated Hepatotoxicity.
van Waterschoot RA; Eman RM; Wagenaar E; van der Kruijssen CM; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2009 Dec; 15(24):7616-7623. PubMed ID: 19996204
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
